Ventas Expands ATM Program to Bolster Capital Flexibility

The latest update is out from Ventas ( (VTR) ).

On May 12, 2026, Ventas finalized a separation and release agreement with retiring executive Peter J. Bulgarelli, under which he will receive a prorated 2026 bonus in exchange for a release of claims and adherence to restrictive covenants, marking a leadership transition in its outpatient medical and research and Lillibridge units. On May 13, 2026, shareholders re-elected all 12 director nominees, approved executive pay on an advisory basis and ratified KPMG as auditor, while on May 15, 2026, the company expanded its at-the-market equity program to allow up to $3 billion in new common stock issuance, enhancing its financial flexibility and potential capital-raising capacity.

The most recent analyst rating on (VTR) stock is a Buy with a $100.00 price target. To see the full list of analyst forecasts on Ventas stock, see the VTR Stock Forecast page.

Spark’s Take on VTR Stock

According to Spark, TipRanks’ AI Analyst, VTR is a Neutral.

The score is driven primarily by improving operating/cash-flow performance and a strongly positive earnings update with raised guidance, reinforced by solid technical momentum. These strengths are tempered by balance-sheet leverage/profitability durability concerns and a significant valuation headwind from the very high P/E.

To see Spark’s full report on VTR stock, click here.

More about Ventas

Ventas, Inc. is a real estate investment trust focused on healthcare and senior living properties, including outpatient medical and research facilities. Through subsidiaries such as Lillibridge Healthcare Services, it serves healthcare providers and research institutions, positioning itself at the intersection of real estate and the growing demand for medical and research infrastructure.

Average Trading Volume: 3,804,647

Technical Sentiment Signal: Buy

Current Market Cap: $44.76B

Learn more about VTR stock on TipRanks’ Stock Analysis page.